0
0 (0%)
X4 Pharmaceuticals, Inc [XFOWW]
Source:
Company Overview
X4 Pharmaceuticals, Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. We have successfully developed our first product, mavorixafor, in its first indication. Mavorixafor is an orally available, small-molecule selective antagonist of chemokine receptor CXCR4.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | (857) 529-8300 |
| Industry | manufacturing |
| CEO | Paula Ragan |
| Website | www.x4pharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2.6 |
| Operating Profit | $-36.4 |
| Net Income | $-37.5 |
| Net Cash | $-43.8 |
Profit Ratios
| Gross Margin | $1.8 |
| Operating Margin | -1,423.6 |
| Profit as % of Revenues | -4.7% |
| Profit as % of Assets | -25.5% |
| Profit as % of Stockholder Equity | -169.1% |
Management Effectiveness
| Return on Equity | -169.1% |
| Return on Assets | -25.6% |
| Turnover Ratio | 1.7% |
| EBITA | $-36.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $146.4 |
| Total Liabilities | $124.3 |
| Operating Cash Flow | $-130.9 |
| Investing Cash Flow | $67 |
| Financing Cash Flow | $20.3 |
